Category list : Technology appraisals

Sort by: Newest first Oldest first A-Z Z-A

  • man using phone

    NHS app to allow patients to order repeat prescriptions

    10 SEP 2018 14:40 By Debbie Andalo

    Pilot testing of a new NHS smartphone app will begin in October 2018, before being rolled out across England in December 2018.

  • Person receiving chemotherapy

    Two cancer drugs approved by NICE after companies cut prices

    24 AUG 2016 15:18

    Two drugs for the treatment of some patients with leukaemia or lung cancer are to be routinely available on the NHS following a recommendation from the National Institute for Health and Care Excellence (NICE). 

  • NICE office logo

    NICE rejects £104,000 lumacaftor/ivacaftor therapy for cystic fibrosis

    20 JUN 2016 16:25

    The high cost of combination treatment lumacaftor/ivacaftor (Orkambi) means it has not been recommended for use in the NHS in England and Wales for cystic fibrosis (CF), draft guidance from the National Institute for Health and Care Excellence (NICE) says

  • Malignant melanoma

    Combination immunotherapy for advanced melanoma gets early approval from NICE

    17 JUN 2016 16:05

    The immunotherapy combination nivolumab/ipilimumab has been recommended for patients with advanced malignant melanoma, according to draft guidance from the National Institute for Health and Care Excellence (NICE). 

  • Sir Hugh Taylor, chair of the Accelerated Access Review and of Guy’s & St Thomas’ NHS Foundation Trust

    ‘One-size-fits-all’ approach will not work for drug evaluation and funding Subscription

    26 APR 2016 10:12 By Ingrid Torjesen

    Evaluation and funding of the most promising and innovative medicines will require a separate approach to other drugs in the future, according to the chair of the government-commissioned accelerated access review.

  • NICE recommends nintedanib Subscription

    10 FEB 2016 13:54

    The National Insitute for Health and Care Excellence (NICE) has recommended nintedanib as an option for treating idiopathic pulmonary fibrosis if the person has between 50% and 80% of their predicted forced vital capacity (FVC); the company provides nintedanib with the discount agreed in the patient access scheme; and treatment is stopped if disease progresses (a confirmed decline in percent predicted FVC of 10% or more) in any 12‑month period. Further details can be found on the

  • NICE recommends prostate cancer drugs Subscription

    10 FEB 2016 10:21

    The National Institute for Health and Care Excellence (NICE) has recommended Radium‑223 dichloride as an option for treating adults with hormone‑relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases, if they have had treatment with docetaxel and the company ...

  • NICE recommends drugs for ankylosing spondilitis Subscription

    9 FEB 2016 12:20

    The National Institute for Health and Care Excellence (NICE) has issued guidance recommending adalimumab, certolizumab pegol, etanercept, golimumab and infliximab, within their marketing authorisations, as options for treating severe active ankylosing spondylitis in adults whose disease has responded inadequately to, or who cannot tolerate, non‑steroidal anti‑inflammatory drugs. Full details of the recommendations can be found on the 

  • NICE recommends drugs for rheumatoid arthritis Subscription

    9 FEB 2016 12:07

    The National Institute for Health and Care Excellence (NICE) has recommended adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept, all in combination with methotrexate, as options for treating rheumatoid arthritis, if the disease is severe (e.g. a disease activity score [DAS28] greater than 5.1) and the disease has not responded to intensive therapy with a combination of conventional disease‑modifying antirheumatic drugs (DMARDs). Companies must ...

  • Evolucumab draft recommendations Subscription

    26 NOV 2015 9:24

    The National Institute for Health and Care Excellence (NICE) has issued draft guidance not recommending evolocumab (Repatha, Amgen) as an option for people with high cholesterol (primary hypercholesterolaemia — heterozygous-familial and non-familial) and mixed dyslipidaemia. The draft guidance can be accessed

Show  10 per page20 per page50 per page

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.

Vardénafil

www.medicaments-24.com

Viagra 25 mg en ligne